The ascendancy of Viagra and its effect on the pharmaceutical landscape presents a intricate question for shareholders. While the initial sales statistics were astounding, the patent has expired, leading to a deluge of copycat alternatives that are eroding revenue. Furthermore, the market is facing difficulties related to aging trends and shifting